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A B S T R A C T
Haptoglobin (Hp) is a major plasma acute-phase glycoprotein, which binds free haemoglobin to neutralize its
toxicity. The HP gene exists as two copy number variants (CNV), Hp1 and HP2, which diﬀer in two ways: serum
Hp level and functional diﬀerences in Hp protein products. Both mechanisms may underlie the HP CNV's in-
ﬂuence on susceptibility and/or outcome in several diseases. A single nucleotide polymorphism rs2000999 has
also been associated with serum Hp level. In a meta-analysis of three studies from England, France and Japan,
with a combined sample size of 1210 participants, we show that rs2000999's eﬀect on circulating Hp level is
independent from that of the HP CNV. The combined use of rs2000999 and the HP CNV can be an important
genetic epidemiological tool to discriminate between the two potential mechanisms underlying diﬀerences
between HP1 and HP2 alleles.
1. Introduction
Haptoglobin (Hp) is a major plasma acute-phase glycoprotein. The
main biological function of Hp is to bind free haemoglobin (Hb) to
prevent the loss of iron and subsequent kidney damage following in-
travascular hemolysis [1]; it may also have immunomodulatory prop-
erties [1]. In humans, the HP locus is polymorphic. The basic structure
of Hp is of an alpha and beta chain that form a monomer; a disulphide
bond between the alpha chains of two monomers leads to the formation
of a dimer in the mature form of Hp. An intragenic duplication of exons
3 and 4 of the ancestral HP gene produced the HP2 allele, after which
recurrent deletions produced the modern HP1 allele [2]. Therefore in-
dividuals could be one of three genotypes: HP1–1, HP2–1 or HP2–2 [3].
This copy number variant (CNV) codes for an extra cysteine residue in
the alpha chain that forms an additional disulphide bond; therefore
trimeric, tetrameric and higher order polymers are formed in in-
dividuals carrying the HP2 allele [3].
The HP CNV may inﬂuence the susceptibility and/or outcome in
several diseases, for example, diabetes mellitus [4,5], atherosclerosis
[6] and cardiovascular disease [7], malignancies [8] and infections [9],
with HP2 conferring higher risk. The HP2 allele is associated with a
dose-dependent reduction in serum Hp level, compared to HP1 (serum
Hp level: HP1–1 > HP2–1 > HP2–2) [10]. The HP1 and HP2 alleles
diﬀer in their ability to clear Hb and may have other functional dif-
ferences relating to protection from Hb-induced oxidative stress [11].
Hence the diﬀerential eﬀects of HP1 and HP2 alleles could be mediated
by a diﬀerence in levels of circulating Hp, or functional diﬀerences in
their protein products, or both.
A single nucleotide polymorphism (SNP) rs2000999 has also been
associated with plasma Hp level, resulting in a dose-dependent varia-
tion across the genotypes: GG > GA > AA [12]. Since rs2000999 is
downstream of the HP gene, its eﬀect is probably mediated via linkage
disequilibrium (LD) with upstream variations, such as the single base-
pair deletion rs35283911 [10]. Up to 45% of the variance in circulating
Hp level is explained by rs2000999 [12]. It is likely that some of the
eﬀects of rs2000999 and the HP CNV on Hp level are independent of
each other [2,10,13].
The aim of this study was to perform a meta-analysis to conﬁrm the
independence of rs2000999 from the HP CNV with respect to circu-
lating Hp level. If rs2000999 truly has an independent eﬀect on Hp
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level, the combined use of rs2000999 and the HP CNV can be an im-
portant genetic epidemiological tool to discriminate between the two
potential mechanisms underlying diﬀerences between HP1 and HP2
alleles: Hp protein function or Hp protein expression level.
2. Material and methods
2.1. Participants
We included studies which: (1) genotyped both the HP CNV and
rs2000999 and (2) genotyped the CNV using gold-standard PCR ap-
proaches (Table 1), rather than imputation from genome-wide array
screening (GWAS). Three studies were identiﬁed at the time of study
planning, and data was made available by the authors. The Avon
Longitudinal Study of Parents and Children (ALSPAC) is a general po-
pulation cohort study [14,15]; lithium heparin plasma Hp level and HP
genetic data was available from 325 participants (159 females and 166
males, Caucasian, age 18 ± 0.33 years). The ALSPAC study website
(http://www.bristol.ac.uk/alspac/researchers/our-data/) contains de-
tails of all the data that is available through a fully searchable data
dictionary and variable search tool. Ethical approval for the study was
obtained from the ALSPAC Ethics and Law Committee and the Local
Research Ethics Committees. The STANISLAS Family Study (SFS) pro-
vided data from 500 French community-dwelling adult women of
European ancestry (mean age 39.6 ± 4.1 years) [12,16]. Soejima et al
consisted of 385 Japanese patients scheduled for blood transfusion (195
females and 190 males, Asian, adults of undetermined age) [13].
Table 1 lists the study characteristics including the methods used for HP
genotyping and circulating Hp level assay.
2.2. Analysis
The contribution of the HP CNV and rs2000999 to circulating Hp
levels was studied within each cohort using multivariate regression
modelling in R (Hp level as outcome, HP CNV as exposure and
rs2000999 as covariate). The interaction terms HP CNV * gender and
rs2000999 * gender were considered, except in the female-only French
cohort. The results of each cohort were combined in a ﬁxed-eﬀects
meta-analysis conducted using the R package metaphor, with the inverse
variance for weighting and the restricted maximum likelihood esti-
mator method as heterogeneity estimator, and assuming a standard
normal distribution to calculate conﬁdence intervals (CI).
3. Results
3.1. Contribution of HP polymorphism to expression
Data from the two mixed gender British and Japanese cohorts and
the female-only French cohort was used to assess the contribution of the
two HP genetic polymorphisms to circulating Hp level. All cohorts were
in Hardy-Weinberg equilibrium (HWE) for both genetic variants
(Supplementary File 1, Table S1). We found evidence of LD between the
two polymorphisms in each cohort (Supplementary File 1, Table S1).
To determine the contribution of HP genetic variation to circulating
Hp level we performed multivariate linear regression where HP CNV
was the exposure and rs2000999 was the covariate and combined the
eﬀects of each cohort in a ﬁxed-eﬀects meta-analysis. The analysis
identiﬁed that the rs2000999 minor allele (A) was associated with a Hp
change of −0.14 g/L (95% CI −0.20 to −0.09, p=2.6× 10−7), and
the HP CNV was also associated with Hp level (for each HP2 allele,
β=−0.189 g/L, 95% CI −0.24 to −0.14, p=1.68×10−15), Fig. 1.
There was no statistical evidence of between study heterogeneity (Co-
chrane Q p-values were > 0.4). The magnitude of eﬀect was larger in
univariate compared to multivariate analysis (cf Figs. 1 and 2). The
French and British studies, which restricted participants to healthy in-
dividuals only, broadly revealed the same results (Figs. 1 and 2).Ta
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Fig. 1. Eﬀect of the HPCNV and rs2000999 on cir-
culating Hp level in multivariate analyses. CNV was
included in the model as a dependent variable and
rs2000999 as a covariate whereas gender was in-
cluded as an interaction term. The labels indicate the
comparison being made; for instance CNV:HP2 in-
dicates the change in Hp level in g/L for every HP2
allele (i.e. the beta coeﬃcient). Gender:M= the
gender is male.
Fig. 2. Eﬀect of HP-CNV and rs2000999 on circulating Hp level in univariate analyses.
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The main eﬀect of gender was assessed in British and Japanese
cohorts (British: rs2000999 p= .69, HP CNV p= .08; Japanese:
rs2000999 p= .10, HP CNV p= .96). There was no interaction of
gender with either the HP CNV or rs2000999 in determining Hp level
(for meta-analysis: rs2000999 p= .4 and HP CNV p= .1, Fig. 2).
The mean Hp level was 0.99 g/L (standard deviation (SD): 047) in
the British cohort, 1.42 g/L (SD: 1.06) in the Japanese cohort and
1.06 g/L (SD: 0.43) in the French cohort. HP2 and rs2000999:A were
more frequent in Japanese versus Caucasian populations (χ2= 27.04
and 71.80 respectively, degrees of freedom=2 and 2 respectively,
p < .00001 in both cases). In a multivariate linear regression, the ef-
fect of ancestry (Asian/European) on Hp level persisted despite con-
trolling for the HP CNV, rs2000999 and gender (Supplementary File 1,
Table S2).
4. Discussion
This meta-analysis of HP genetic variation and circulating Hp con-
centration across British, Japanese and French populations showed
that: (1) both rs2000999 and HP CNV contribute to Hp level, (2) the
eﬀects of rs2000999 and the HP CNV are independent of each other, i.e.
LD does not fully account for their combined eﬀects on Hp level. The
beta coeﬃcients of univariate regression analyses were consistently
higher than the respective multivariate analyses indicating that LD
accounts for some of the eﬀect seen in univariate analyses, but clear and
strong independent eﬀects were observed.
Other factors potentially inﬂuencing circulating Hp level include
age, gender and ancestry. We could not include age as a covariate since
participants in the British study were roughly of the same age, and the
Japanese study did not collect age data. However, in the French cohort,
age above 18 years did not inﬂuence Hp level [12,17]. Gender may
aﬀect circulating Hp level [18], so it was included as a covariate, but it
did not have a signiﬁcant relationship to Hp level in our analyses.
Ancestry also impacts on circulating Hp level [13]. Some of the eﬀect of
ancestry could be due to inter-population diﬀerences in the frequencies
of the HP CNV and rs2000999, but we show here that the eﬀect of
Asian/European status on Hp level persisted despite controlling for the
HP CNV, rs2000999 and gender. This residual eﬀect of ancestry could
be due to other genetic determinants. However, comparison of studies
performed in diﬀerent populations needs to be interpreted with cau-
tion, since diﬀerences in Hp level could also be due to methodological
diﬀerences in Hp assay technique between studies.
Strengths of this study include the large sample size and the mul-
tivariate nature of the analysis, controlling for gender, ancestry, HP
CNV and HP SNP. Two of the populations (French and British) were
unselected individuals allowing us to perform sensitivity analysis
without the confounding factor of disease that exists in the Japanese
study. Also the HP CNV was genotyped using a gold-standard PCR ap-
proach, not determined by imputation.
This study has a number of limitations. Other covariates potentially
aﬀecting Hp level, such as body mass index and cigarette consumption
[17], were not available. The Japanese cohort was not community-
based since it was a population of patients requiring blood transfusion.
This could have been responsible for the observed higher Japanese
frequency of HP2 and rs2000999:A, despite the population being in
HWE. It is still possible that some of the higher Hp level in the Japanese
cohort, unexplained by the HP CNV and rs2000999, was driven by
underlying medical conditions in people requiring blood transfusion, as
well as other population-speciﬁc genetic determinants.
5. Conclusions
In conclusion, we show that the HP CNV and SNP both contribute to
circulating Hp level, independent of each other. Using these two HP
genetic variations together is a valuable genetic epidemiological tool to
dissect the mechanism underlying the diﬀerential eﬀect of HP1 and
HP2 alleles in disease, namely whether this is through Hp level or
diﬀerences in function between Hp polymers.
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